VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

C. parvum DNA vaccine encoding CP15/60 C. parvum DNA vaccine encoding CP23
Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0011502
  • Type: DNA vaccine
  • Status: Research
  • Antigen: C. parvum sporozoite surface antigen CP15/60
  • CP15/60 gene engineering:
    • Type: DNA vaccine construction
    • Description: Recombinant pCP15/60 plasmid DNA was prepared using standard procedures and resuspended to 1 mg/ml in 0.15 M NaCl. Sera was collected from multiparous Holstein–Fresian cows at 8–12 weeks prior to parturition and tested by IFA for presence of Ab to C. parvum oocysts (Jenkins et al., 1999).
    • Detailed Gene Information: Click Here.
  • Vector: pCP15/60 (Jenkins et al., 1999)
  • Immunization Route: Parenchymal injection
  • Vaccine Ontology ID: VO_0011362
  • Type: DNA vaccine
  • Status: Research
  • Antigen: Cp23 antigen
  • CP23 gene engineering:
    • Type: DNA vaccine construction
    • Description: The C. parvum 27-kDa antigen coding sequence (GenBank accession number U34390) was amplified from a Cp23- pGEX 4T-2 clone. The fragment was cloned into the EcoRI and NotI restriction enzyme sites of the pUMVC4b expression vector (Adevron, Fargo, ND, USA). This vector has a cytomegalovirus promoter and immunoadjuvant site that enhances immune responses. Plasmids containing inserts (pUMVC4b-Cp23) and plasmids without inserts (pUMVC4b) were transformed into UltraMAX™ DH5a-FT™ Competent Cells (Invitrogen, Carlsbad, CA, USA), purified, and dissolved in sterile Tris–borate–ethylenediamine tetraacetic acid (TBE). After cloning, the sequence of the resulting clone was confirmed by automated DNA sequencing (Ehigiator et al., 2007).
    • Detailed Gene Information: Click Here.
  • Vector: pUMVC4b expression vector
  • Immunization Route: Subcutaneous injection
Host Response Host Response

Mouse Response

  • Host Strain: C57BL/6NCr
  • Vaccination Protocol: Cows (n=2) with negligible titers (<1:50) to C. parvum oocysts were immunized at 6, 4 and 2 weeks prior to parturition with 1 mg of plasmid DNA by needle-syringe injection into the parenchymal tissue of the mammary gland. Colostrum from the cows was also tested for conferring passive immunity against C. parvum infection by oral administration to immunosuppressed adult inbred mice. Immune colostrum and control colostrum were administered to separate groups of dexamethasone (DEX)-treated adult C57BL/6NCr mice beginning 12 h before and at 12 h intervals for 3 days after oral C. parvum oocyst infection (Jenkins et al., 1999).
  • Challenge Protocol: In three separate experiments, DEX-treated mice (n=4 per group, six groups per treatment) received 250 μl of HBC or NBC by gastric intubation using a 26 ga. gavage needle 12 h prior to C. parvum infection. At 0 h, the mice were infected with either 103 or 104 C. parvum oocysts and given 250 μl of either HBC or NBC. Control mice were given H2O and either infected or not infected with C. parvum oocysts (Jenkins et al., 1999).
  • Efficacy: Mice receiving immune colostrum showed partial protection (about 50% reduction) against intestinal C. parvum development compared to mice receiving control colostrum. This protection was evident at a challenge dose of 103 C. parvum oocysts per mouse (Jenkins et al., 1999).

Mouse Response

  • Host Strain: C57BL/6 KO
  • Vaccination Protocol: Mice (ten per group) were injected subcutaneously in the ear with 100-μg plasmid pUMVC4b-Cp23 in TBE on days 0, 14, and 29. Mice in the control group were injected with either the vector pUMVC4b without the insert or with PBS (Ehigiator et al., 2007).
  • Challenge Protocol: The different treatment groups of IL-12p40KO mice were challenged with a dose of 1,000 C. parvum oocysts by oral gavage 2 weeks after the last immunization (Ehigiator et al., 2007).
  • Efficacy: Cp23-DNA vaccination induced a 50-60% reduction in oocysts shedding, indicating a partial protection against C. parvum infection in IL-12 KO mice (Ehigiator et al., 2007).
  • Host Ighg1 response
    • Description: Six weeks post immunization, mice were bled and antibody responses were measured by ELISA. IgG1 responses were significantly higher in Cp23 vaccinated mice than vector (control) immunized mice (Ehigiator et al., 2007).
    • Detailed Gene Information: Click Here.
  • Host Ighv1-9 response
    • Description: Six weeks post immunization, mice were bled and antibody responses were measured by ELISA. IgG2a responses were significantly higher in Cp23 vaccinated mice than vector (control) immunized mice (Ehigiator et al., 2007).
    • Detailed Gene Information: Click Here.
References References
Jenkins et al., 1999: Jenkins MC, O'Brien C, Trout J, Guidry A, Fayer R. Hyperimmune bovine colostrum specific for recombinant Cryptosporidium parvum antigen confers partial protection against cryptosporidiosis in immunosuppressed adult mice. Vaccine. 1999; 17(19); 2453-2460. [PubMed: 10392628].
Ehigiator et al., 2007: Ehigiator HN, Romagnoli P, Priest JW, Secor WE, Mead JR. Induction of murine immune responses by DNA encoding a 23-kDa antigen of Cryptosporidium parvum. Parasitology research. 2007; 101(4); 943-950. [PubMed: 17487508].